<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> valued at $690.4 million as shares rise marginally in market debutJan 31 (Reuters) - Shares of Maze Therapeutics MAZE.O rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.
(Reporting by Ateev Bhandari in Bengaluru; Editing by Alan Barona)
((Ateev.Bhandari@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。